Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Marin D, et al. Among authors: goldman j. J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385986 Free PMC article.
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.
Khorashad JS, Wagner S, Greener L, Marin D, Reid A, Milojkovic D, Patel H, Willimott S, Rezvani K, Gerrard G, Loaiza S, Davis J, Goldman J, Melo J, Apperley J, Foroni L. Khorashad JS, et al. Among authors: goldman j. Haematologica. 2009 Jun;94(6):861-4. doi: 10.3324/haematol.2008.003715. Epub 2009 Apr 18. Haematologica. 2009. PMID: 19377081 Free PMC article.
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D. Ibrahim AR, et al. Among authors: goldman j. Blood. 2011 Apr 7;117(14):3733-6. doi: 10.1182/blood-2010-10-309807. Epub 2011 Feb 23. Blood. 2011. PMID: 21346253 Free PMC article.
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.
Ibrahim AR, Clark RE, Holyoake TL, Byrne J, Shepherd P, Apperley JF, Milojkovic D, Szydlo R, Goldman J, Marin D. Ibrahim AR, et al. Among authors: goldman j. Haematologica. 2011 Dec;96(12):1779-82. doi: 10.3324/haematol.2011.049759. Epub 2011 Aug 22. Haematologica. 2011. PMID: 21859733 Free PMC article. Clinical Trial.
BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.
Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L. Alikian M, et al. Among authors: goldman j. Am J Hematol. 2012 Mar;87(3):298-304. doi: 10.1002/ajh.22272. Epub 2012 Jan 9. Am J Hematol. 2012. PMID: 22231203 Free article. Review.
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D. Neelakantan P, et al. Among authors: goldman j. Blood. 2013 Apr 4;121(14):2739-42. doi: 10.1182/blood-2012-11-466037. Epub 2013 Feb 4. Blood. 2013. PMID: 23380743 Free PMC article. Clinical Trial.
3,228 results